Skip to main content

and
  1. Article

    Open Access

    Selective and noncovalent targeting of RAS mutants for inhibition and degradation

    Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 1...

    Kai Wen Teng, Steven T. Tsai, Takamitsu Hattori, Carmine Fedele in Nature Communications (2021)